EN | UA
EN | UA

Help Support

Back

Study explores effect of baricitinib vs. dexamethasone in hospitalized COVID-19 people

covid_therapy covid_therapy
covid_therapy covid_therapy

What's new?

In hospitalized COVID-19 patients, baricitinib + remdesivir and dexamethasone + remdesivir led to comparable mechanical ventilation-free survival by day 29.

A randomized, double-blind, double placebo-controlled trial (ACTT-4) illustrated that both baricitinib and dexamethasone (in combination with remdesivir) were associated with similar mechanical ventilation-free survival by day 29 in adults hospitalized with coronavirus infection and who needed supplemental oxygen. Researchers aimed to evaluate efficacy and safety of baricitinib + remdesivir versus dexamethasone + remdesivir to prevent progression to death or mechanical ventilation in COVID-19.

Out of 1047, 1010 hospitalized patients (aged ≥18 years, mean age 58·3 years) who need supplemental oxygen given by high-flow (>15 L/min), low-flow (≤15 L/min), or non-invasive mechanical ventilation modalities were recruited.  Participants were randomly divided (1:1) into baricitinib + remdesivir + placebo group (n = 516, 51%) and dexamethasone + remdesivir + placebo group (n = 494, 49%).

The recruited volunteers were administered remdesivir (≤ten days) and either dexamethasone (or matching intravenous placebo) for maximum of ten days or baricitinib (or matching oral placebo) for maximum of fourteen days. In modified intention-to-treat population, the inter-group difference in mechanical ventilation-free survival was the major endpoint ascertained. Safety evaluation was carried out in the as-treated population, encompassing all the people who were administered 1 dose of the study drug.

By day 29, both the study groups had comparable mechanical ventilation-free survival (risk difference 0·6). Table 1 shows the percentage of people with at least 1 adverse event (risk difference 7·5%), at least one treatment-related adverse event  (risk difference 6·0%), and severe or life-threatening grade 3 or 4 adverse events (risk difference 7·7%).

In contrast to the baricitinib + remdesivir + placebo group, the odds ratio for enhanced status in the dexamethasone + remdesivir + placebo group was found to be 1·01. To conclude, in SARS-CoV-2 infected people who require supplemental oxygen therapy, baricitinib in combination with remdesivir and dexamethasone in combination with remdesivir exhibited comparable efficacy in terms of mechanical ventilation-free survival. However, dexamethasone was related to more adverse events.

Source:

The Lancet

Article:

Baricitinib versus dexamethasone for adults hospitalized with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Authors:

Cameron R Wolfe et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: